June 27th 2025
A retrospective study finds no significant difference in treatment failure between patients with obesity and those without.
The Top 5 Infectious Disease News Stories Week of January 18-25
January 25th 2025This week, local health department's role in combating HAIs and AMR by strengthening infection prevention, global efforts to address fungal infections, and pandemic preparedness continue to face challenges, and more.
Read More
Do We Have New Data for Optimal Treatments of Candida-Related Prosthetic Joint Infections?
January 14th 2025The choice between debridement and implant exchange affects treatment outcomes for Candida-related prosthetic joint infections, highlighting the need for standardized guidelines and further research.
Read More
Echinocandin Dosing Considerations in Obese Patients: A Review
Published: November 18th 2024 | Updated: November 18th 2024Obesity significantly impacts the pharmacokinetics (PK) of antifungal drugs like echinocandins, including volume of distribution (Vd) and clearance. However, despite these PK differences, current clinical evidence generally does not support the need for universal dose adjustments in obese patients. Clinicians should consider personalized dosing based on patient characteristics, infection severity, and specific drug properties due to echinocandins' favorable safety profiles.
Read More